Takeda Pharmaceutical Co. Ltd. and Resolve Therpeutics have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease Fc fusion protein, will begin clinical development later this year. Resolve has additional candidates in preclinical development that target autoantibody-containing immune complexes, which are thought to be the most frequent trigger of lupus.
Resolve will conduct all development work through the first RSLV-132 Phase Ib/IIa trial, after which Takeda has the exclusive option to license the lead compound and all other compounds from the Resolve platform. Takeda would then assume lead responsibility for worldwide development and commercialization. Takeda will contribute funding for continued development of RSLV-132 through an initial payment of $8 million. Upon exercising its option, Takeda would pay Resolve an option fee plus additional development milestones totaling $247 million, as well as royalties on product sales.
"This collaboration with Resolve is very exciting as its innovative pipeline of nuclease fusion proteins has the potential to provide a new approach to helping lupus patients," said Tetsuyuki Maruyama, Ph.D., general manager of the Pharmaceutical Research Division at Takeda.
"We are delighted to begin work with our Takeda colleagues," said James Posada, Ph.D., MBA, chief executive officer of Resolve. "We feel strongly that Takeda's expertise, commitment to inflammation, and considerable resources will give the Resolve compounds the best possible chance of success."